The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
Initiative focuses on early diagnosis, gut health awareness and long-term gluten-free care for children with celiac disease
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
The country’s strength lies not just in technology availability but in adoption behaviour
Subscribe To Our Newsletter & Stay Updated
